A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression.

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and is the third most common cause of death from cancer. Sorafenib is the only drug which improves survival in first line advanced HCC. Sorafenib has been associated with several dermatologic toxicities and toxic effects have been related to a better treatment response. We report the case of a well-circumscribed panniculitis and necrotizing vasculitis due to sorafenib, appeared in disease progression in a man affected by advanced HCC.

[1]  R. Verma,et al.  Sorafenib and sunitinib: A dermatologist's perspective , 2014, Indian dermatology online journal.

[2]  J. Montastruc,et al.  Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors , 2013, European Journal of Clinical Pharmacology.

[3]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[4]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[5]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[6]  S. Wilhelm,et al.  Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models , 2007, Cancer Chemotherapy and Pharmacology.

[7]  J. Llovet,et al.  Systematic review: evidence‐based management of hepatocellular carcinoma – an updated analysis of randomized controlled trials , 2006, Alimentary pharmacology & therapeutics.

[8]  D. Strumberg,et al.  Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? , 2006, European journal of cancer.

[9]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[10]  M. Atanassova,et al.  Hepatocellular carcinoma associated with paraneoplastic erythema nodosum and polyarthritis. , 2003, Journal of hepatology.

[11]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[12]  G. Dusheiko,et al.  Management of hepatocellular carcinoma. , 1992, Journal of hepatology.

[13]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.